Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer.
OBJECTIVE
Positron emission tomographic maximal standardized uptake value has been shown to predict survival after resection of non-small cell lung cancer. The relative prognostic benefit of maximal standardized uptake value with respect to other clinical/pathologic variables has not been defined.


METHODS
We reviewed patients who had positron emission tomographic imaging and an R0 resection for non-small cell lung cancer between January 1, 2000, and December 31, 2004, without induction or adjuvant therapy. The associations between overall survival, histology, pathologic TNM stage, pathologic tumor diameter, and standardized uptake value were tested.


RESULTS
Four hundred eighty-seven patients met the study criteria. Median follow-up was 25.8 months. By using the median values for tumor size (2.5 cm) and standardized uptake value (5.3), standardized uptake value was an independent predictor of survival (P = .03), adjusting for tumor size (P = .02) and histology (P < .01). The optimal standardized uptake value for stratification was identified as 4.4, and this value was identified as an independent predictor of survival (P = .03) after adjusting for clinical TNM stage. Standardized uptake value was not an independent predictor of survival (P = .09), adjusting for pathologic TNM stage (stage IA vs IB vs stage II-IV, P < .01).


CONCLUSIONS
Standardized uptake value does not add to the prognostic significance of pathologic TNM stage. Standardized uptake value was an independent prognostic factor from clinical TNM stage.
Downey
Robert J
RJ
Thoracic Surgery Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. downeyr@mskcc.org
Akhurst
Timothy
T
Gonen
Mithat
M
Park
Bernard
B
Rusch
Valerie
V
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000473:pathology / Q000601:surgery; D016009:Chi-Square Distribution; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D012189:Retrospective Studies; D016019:Survival Analysis
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18